mGlu2/3 Negative Allosteric Modulators for Intellectual Disabilities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are ineffective for intellectual disabilities, which are characterized by significant limitations in intellectual functioning and adaptive behavior, with no efficient biological or pharmaceutical solutions available.
Innovation Solution
Development of mGlu2/3 negative allosteric modulators, specifically compounds and pharmaceutical compositions that interact with metabotropic glutamate receptors to modulate their activity, offering a potential treatment for intellectual disabilities by addressing excessive receptor activation in the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mGlu2/3 negative allosteric modulators are used to treat intellectual disabilities, then cognitive functions are improved and disease progression is delayed, but the mechanism of action involves complex receptor modulation in the central nervous system
Solution Approach 1:
The patent employs mGlu2/3 negative allosteric modulators as intermediary substances that bind to metabotropic glutamate receptors in the central nervous system. These compounds act as mediators between the administered treatment and the underlying pathological mechanism, correcting excessive receptor activation without requiring direct manipulation of complex neural circuits. The modulators serve as chemical intermediaries that translate pharmacological intervention into therapeutic effect.
2Reliability
If conventional treatments are used for intellectual disabilities, then treatment simplicity is maintained, but treatment effectiveness is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the biochemical parameters of neurotransmission through mGlu2/3 receptor modulation. Instead of attempting to simplify complex neural pathways, the invention changes the activation parameters of specific receptors, thereby altering the functional output of neural circuits involved in cognitive processing. This approach achieves treatment effectiveness by adjusting molecular-level parameters rather than simplifying macro-level treatment protocols.
3Reliability
If mGlu2/3 negative allosteric modulators target excessive receptor activation in cortical regions and hippocampus, then cognitive function improvement is achieved, but the risk of off-target effects in the central nervous system increases
Solution Approach 1:
The patent applies local quality by targeting mGlu2/3 receptors in specific brain regions (cortical regions and hippocampus) where they are most relevant to cognitive function. The negative allosteric modulators exhibit region-specific effects due to the differential distribution and density of mGlu2/3 receptors throughout the central nervous system. This localized modulation approach maximizes therapeutic benefit in cognitive-related areas while minimizing off-target effects in other brain regions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of mGlu2/3 negative allosteric modulators demonstrates therapeutic potential in improving cognitive functions and potentially delaying the progression of intellectual disabilities by correcting excessive receptor activation in the central nervous system, particularly in cortical regions and hippocampus.
Implementation Method 1
mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities
Data Source
AI summary
This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.